Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, January 28, 2015
Technology Networks
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Cancer-Causing Virus Blocks Human Immune Response
Epstein-Barr virus shown to outwit the human immune response using microRNAs.
Major Study Links Gene to Drug Resistance in Testicular Cancer
Researchers used a genetic technique called whole-exome sequencing to examine tumour samples.
New Blood Test For Aggressive Bone Cancer
Researchers at the University of East Anglia are developing a simple blood test to diagnose bone cancer thanks to funding from the Big C.
NIH Researchers Tackle Thorny Side of Gene Therapy
Pre-clinical studies in mice reveal ways to reduce cancer risk with modified treatment.
Tumor Suppressor Protein Plays Key Role In Maintaining Immune Balance
St. Jude Children’s Research Hospital scientists show that the PTEN tumor suppressor protein is essential for proper regulatory T cell function; discovery offers new focus for improving treatment of autoimmune diseases.
GRP78 Protein Possible Universal Therapeutic Target
Drug combination including Viagra is effective tool in targeting the protein.
Bad Luck of Random Mutations Plays Predominant Role in Cancer, Study Shows
Statistical modeling links cancer risk with number of stem cell divisions.
3-D Culture System for Pancreatic Cancer has Potential to Change Therapeutic Approaches
Organoid technology with human tissue provides a model for full progression of the disease.
Targeting The Cell’s ‘Biological Clock’
Researchers target the cell’s ‘biological clock’ in promising new therapy to kill cancer cells, shrink tumor growth.
Whole-Genome Sequencing Successfully Identifies Cancer-Related Mutations
UT Southwestern Medical Center cancer researchers have demonstrated that whole-genome sequencing can be used to identify patients’ risk for hereditary cancer.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn